The short version of freeze-thaw cycling fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-24. Anything still debated is marked as such rather than presented as settled.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
=== Overview === The Office of Alternative Medicine (OAM) was established in October 1991 by the United States Congress. The OAM was expanded from an office into a center and renamed the National Center for Complementary and Alternative Medicine (NCCAM) in October 1998. It is one of several centers within the National Institutes of Health (NIH). The founding director of the center was Stephen Straus. In 2008, Josephine Briggs became the second director of NCCAM. The NCCAM was renamed the National Center for Complementary and Integrative Health (NCCIH) in December 2014. Helene Langevin was director from August 2018 to November 2025. The 2014 name change to NCCIH has been described by critics as an attempt by the center to mitigate criticism by avoiding the term "alternative" and distancing itself from having funded studies of questionable merit. The 2001 mission statement of the NCCAM stated that it was "dedicated to exploring complementary and alternative healing practices in the context of rigorous science; training complementary and alternative medicine researchers; and disseminating authoritative information to the public and professionals." As NCCIH, the mission statement is "to define, through rigorous scientific investigation, the usefulness and safety of complementary and alternative medicine interventions and their roles in improving health and health care".
=== Actinium-226 === Actinium-226 is an isotope of actinium with a half-life of 29.37 hours. It mainly (83%) undergoes beta decay, sometimes (17%) undergo electron capture, and rarely (0.006%) undergo alpha decay. There are researches on 226Ac to use it in SPECT.
Lactoferrin (LF), also known as lactotransferrin (LTF), is a multifunctional protein found in milk and mucus which is encoded by the LTF gene in humans. Lactoferrin functions as an antimicrobial protein, and also impacts the body's immune response in a complex way, with both pro- and anti-inflammatory effects. This protein is part of the transferrin family. Lactoferrin is a globular glycoprotein with a molecular mass of about 80 kDa that is widely represented in various secretory fluids, such as milk, saliva, tears, and nasal secretions. Lactoferrin is also present in secondary granules of PMNs and is secreted by some acinar cells. Lactoferrin can be purified from milk or produced recombinantly. Human colostrum ("first milk") has the highest concentration, followed by human milk, then cow milk (150 mg/L). Lactoferrin is one of the components of the immune system of the body; it has antimicrobial activity (bacteriocide, fungicide) and is part of the innate defense, mainly at mucosas. It is constantly produced and released into saliva, tears, as well as seminal and vaginal fluid. Lactoferrin provides antibacterial activity to human infants. Lactoferrin interacts with DNA and RNA, polysaccharides and heparin, and shows some of its biological functions in complexes with these ligands. Lactoferrin supplements reduce the risk of respiratory tract infections, based on a recent meta-analysis of randomized controlled trials.
Dominic Lawson, Former editor of The Spectator magazine and Sunday Telegraph newspaper, has been writing column for The Independent since 2006; also writes for the Sunday Times Nigella Lawson, (born 6 January 1960) is an English food writer and television cook. In 1998, her first cookery book, How to Eat, was published and sold 300,000 copies, becoming a best-seller. Her second book, How to Be a Domestic Goddess, was published in 2000, winning the British Book Award for Author of the Year. Nicole Lampert, journalist and commentator. Former show business editor for the Daily Mail. Columnist for the Jewish Chronicle. Writes extensively about antisemitism and Israel for national newspapers. Norman Lebrecht (born 11 July 1948) is a British music journalist and author who specialises in classical music. Lebrecht worked at the Kol Yisrael news department, part of the Israel Broadcasting Authority. He returned to London in 1972, where he was a news executive Visnews Ltd. from 1973 to 1978;was a special contributor to The Sunday Times until 1991; in 2019, Lebrecht published Genius and Anxiety: How Jews Changed the World, 1847–1947. It was published by Oneworld (UK) in October 2019 and by Simon & Schuster (USA) in December 2019. Natasha Lehrer; journalist, writer and literary translator; her translations have received multiple awards, and been shortlisted for several prizes; was joint winner of Scott Moncrieff Prize for translation of Nathalie Léger's Suite for Barbara Loden.
Sources: en.wikipedia.org
== Historical context == In 1992, Stephen Kent and Martina Schnölzer at The Scripps Research Institute developed the "Chemical Ligation" concept, the first practical method to covalently condense unprotected peptide segments; the key feature of chemical ligation is formation of an unnatural bond at the ligation site. Just two years later in 1994, Philip Dawson, Tom Muir and Stephen Kent reported "Native Chemical Ligation", an extension of the chemical ligation concept to the formation of a native amide ('peptide') bond after initial nucleophilic condensation formed a thioester-linked condensation product designed to spontaneously rearrange to the native amide bond at the ligation site. Theodor Wieland and coworkers had reported the S-to-N acyl shift as early as 1953, when the reaction of valine-thioester and cysteine amino acid in aqueous buffer was shown to yield the dipeptide valine-cysteine. The reaction proceeded through the intermediacy of a thioester containing the sulfur of the cysteine residue. However, Wieland's work did NOT lead to the development of the native chemical ligation reaction. Rather, the study of amino acid thioester reactions led Wieland and others to develop the 'active ester' method for the synthesis of protected peptide segments by conventional chemical methods carried out in organic solvents.
On the other hand, by inhibiting miR-33 function, the level of ABCA1 is increased, which increases the cholesterol efflux to apoA-1. Suppression of miR-33 will lead to less cellular cholesterol and higher plasma HDL level through the regulation of ABCA1 expression.
=== Osteoblasts === Osteoblasts are the major cellular component of bone. Osteoblasts arise from mesenchymal stem cells (MSC). MSC give rise to osteoblasts, adipocytes, and myocytes among other cell types. Osteoblast quantity is understood to be inversely proportional to that of marrow adipocytes which comprise marrow adipose tissue (MAT). Osteoblasts are found in large numbers in the periosteum, the thin connective tissue layer on the outside surface of bones, and in the endosteum. Normally, almost all of the bone matrix, in the air breathing vertebrates, is mineralized by the osteoblasts. Before the organic matrix is mineralized, it is called the osteoid. Osteoblasts buried in the matrix are called osteocytes. During bone formation, the surface layer of osteoblasts consists of cuboidal cells, called active osteoblasts. When the bone-forming unit is not actively synthesizing bone, the surface osteoblasts are flattened and are called inactive osteoblasts. Osteocytes remain alive and are connected by cell processes to a surface layer of osteoblasts. Osteocytes have important functions in skeletal maintenance.
Sources: en.wikipedia.org
== Ruler of Xikang (1933–1949) == After the disastrous Two-Liu War, Liu Wenhui retreated into Xikang, basing himself in the town of Ya'an. He focused his energies on ruling the region, which he aimed to establish as an official province of China. Kim Hee-shin believes that facing the need to secure his rule in Xikang, Liu began taking an interest in the province's affairs.
=== Thrombocytopenia === Immune thrombocytopenia (ITP) — formerly known as immune thrombocytopenic purpura and idiopathic thrombocytopenic purpura Splenomegaly Gaucher's disease Familial thrombocytopenia Chemotherapy Babesiosis Dengue fever Onyalai Thrombotic thrombocytopenic purpura HELLP syndrome Hemolytic–uremic syndrome Drug-induced thrombocytopenic purpura (five known drugs — most problematic is heparin-induced thrombocytopenia (HIT) Pregnancy-associated Neonatal alloimmune associated Aplastic anemia Transfusion-associated Pseudothrombocytopenia Vaccine-induced immune thrombotic thrombocytopenia (VITT)
3D food printing is the process of manufacturing food products using a variety of additive manufacturing techniques. Most commonly, food grade syringes hold the printing material, which is then deposited through a food grade nozzle layer by layer. The most advanced 3D food printers have pre-loaded recipes on board and also allow the user to remotely design their food on their computers, phones or some IoT device. The food can be customized in shape, color, texture, flavor or nutrition, which makes it very useful in various fields such as space exploration and healthcare.
== Research == More than 160 faculty members at the University of Texas Health Science Center at San Antonio are actively involved in biomedical and clinical research and educational activities that range from the molecular genetics of aging to issues of health care for the elderly population. Research at the Barshop Institute spans the continuum from basic discovery science to translational and clinical research aimed at extending healthspan and improving quality of life in older adults. Investigators study the fundamental biological processes that drive aging—including cellular senescence, mitochondrial dysfunction, metabolism, inflammation, genomic instability, and impaired tissue regeneration—and apply these discoveries to develop strategies for preventing or treating age-related diseases. Major areas of investigation include Alzheimer's disease and related dementias, cardiovascular disease, type 2 diabetes and metabolic disorders, cancer, frailty, sarcopenia, osteoporosis, and age-associated liver disease. Through the integration of laboratory research, animal models, clinical trials, and population-based studies, Barshop Institute scientists are advancing new therapeutic approaches that target the underlying mechanisms of aging to delay the onset of chronic disease, preserve physical and cognitive function, and promote healthy longevity.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.